As Out-of-Pocket Costs Rise, Medicare Part D Beneficiaries Have Limited Access to New Generic Drugs

Access to newly launched generic drugs is far more restricted for Medicare Part D beneficiaries compared to those with commercial coverage, according to a July report from the Association for Accessible Medicines (AAM), a trade association representing generic drug manufacturers. The report analyzed formulary and drug benefit design data from MMIT (AIS Health’s parent company), finding that just over 20% of 2020’s newly launched generic drugs were covered under Medicare formularies in 2021 vs. 66% under commercial formularies. And when Part D plans do cover new generics, they’re far less likely to be placed on a generic tier, as the Coverage Gap Discount Program (CGDP) incentivizes payers to prefer brand drugs. Meanwhile, the Kaiser Family Foundation (KFF) reported that the influx of new, expensive drugs coming to market is causing an ever-increasing number of Part D beneficiaries to hit the catastrophic threshold, with cumulative beneficiary spending from 2010 to 2019 reaching nearly $10 billion. Researchers suggested several reforms that could help mitigate these issues. The KFF report advocated for adding an out-of-pocket (OOP) spending cap to Part D, while AAM proposed eliminating the CGDP, decreasing payer cost-sharing for generics and biosimilars and allowing for the creation of generic specialty tiers.

© 2022 MMIT
Jinghong Chen

Jinghong Chen Reporter

Jinghong produces infographics and data stories on health insurance and specialty pharmacy for AIS Health. She graduated from Missouri School of Journalism with a focus on data journalism and international reporting. Before joining AIS in 2018, she worked at WBEZ, Al Jazeera English and The New York Times Chinese.

Related Posts

stethoscope
September 15

In ‘Early Innings’ of Major Retail Collabs, UnitedHealth-Walmart Make Medicare Play

READ MORE
medicaid-form
September 15

TennCare Acquiesces to CMS’s Demands for Demo Revisions

READ MORE
physicians-having-a-meeting
September 15

Health Systems May See More Savings With Medicare Advantage vs. Medicare ACOs

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today